Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06048094 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery

Study acronym: FACILITATE
StatusRecruiting
PhasePhase 1
Started2024-04-11
View on ClinicalTrials.gov ↗

Amendment history

2026-05-18
Study Status, Contacts/Locations v5
Primary completion date2026-05→2032-06
Completion date2027-05→2033-05
Study sitescontacts updated at 1 of 1 site
2025-05-15
Study Status v4
Re-verified, no change to tracked fields
2024-04-16
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v3
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-05→confirmed 2024-04-11
Study sitesdetails revised at 1 of 1 site
2024-03-07
Study Status v2
Primary completion date2026-02→2026-05
Completion date2027-02→2027-05
Start date2024-02→2024-05
2023-12-06
Study Status v1
Primary completion date2025-11→2026-02
Completion date2026-11→2027-02
Start date2023-11→2024-02
2023-09-15
Original filing
This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as a biomarker to measure response or progression of brain metastasis after SRS.
Trial Details
NCT Number NCT06048094
Lead Sponsor Baptist Health South Florida
Collaborators: Blue Earth Diagnostics
Conditions Brain Metastases, Brain Metastases, Adult, Brain Cancer
Enrollment 46 participants
Start Date 2024-04-11
Primary Completion 2032-06 (estimated)
Study Completion 2033-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-20